BOUCHERVILLE, QC, Aug. 4, 2025 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) ("LSL Pharma" or the "Corporation"), a Canadian integrated pharmaceutical company, today announced that it has completed the early redemption and cancellation of all issued and outstanding 11.0% Unsecured Convertible Debentures (originally scheduled to mature on October 31, 2028) (the " Debentures").
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
LSL PHARMA GROUP ANNOUNCES THE COMPLETION OF EARLY REDEMPTION OF ALL 11% UNSECURED CONVERTIBLE DEBENTURES
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
